Alam Uazman, Anson Matthew, Meng Yanda, Preston Frank, Kirthi Varo, Jackson Timothy L, Nderitu Paul, Cuthbertson Daniel J, Malik Rayaz A, Zheng Yalin, Petropoulos Ioannis N
Department of Cardiovascular & Metabolic Medicine, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool L69 3BX, UK.
Division of Diabetes, Endocrinology and Gastroenterology, Institute of Human Development, University of Manchester, Manchester M13 9PL, UK.
J Clin Med. 2022 Oct 20;11(20):6199. doi: 10.3390/jcm11206199.
Corneal confocal microscopy (CCM) is a rapid non-invasive in vivo ophthalmic imaging technique that images the cornea. Historically, it was utilised in the diagnosis and clinical management of corneal epithelial and stromal disorders. However, over the past 20 years, CCM has been increasingly used to image sub-basal small nerve fibres in a variety of peripheral neuropathies and central neurodegenerative diseases. CCM has been used to identify subclinical nerve damage and to predict the development of diabetic peripheral neuropathy (DPN). The complex structure of the corneal sub-basal nerve plexus can be readily analysed through nerve segmentation with manual or automated quantification of parameters such as corneal nerve fibre length (CNFL), nerve fibre density (CNFD), and nerve branch density (CNBD). Large quantities of 2D corneal nerve images lend themselves to the application of artificial intelligence (AI)-based deep learning algorithms (DLA). Indeed, DLA have demonstrated performance comparable to manual but superior to automated quantification of corneal nerve morphology. Recently, our end-to-end classification with a 3 class AI model demonstrated high sensitivity and specificity in differentiating healthy volunteers from people with and without peripheral neuropathy. We believe there is significant scope and need to apply AI to help differentiate between peripheral neuropathies and also central neurodegenerative disorders. AI has significant potential to enhance the diagnostic and prognostic utility of CCM in the management of both peripheral and central neurodegenerative diseases.
角膜共焦显微镜检查(CCM)是一种快速、无创的体内眼科成像技术,用于对角膜进行成像。历史上,它被用于角膜上皮和基质疾病的诊断和临床管理。然而,在过去20年中,CCM越来越多地用于对各种周围神经病变和中枢神经退行性疾病中的基底膜下小神经纤维进行成像。CCM已被用于识别亚临床神经损伤,并预测糖尿病周围神经病变(DPN)的发展。通过手动或自动量化角膜神经纤维长度(CNFL)、神经纤维密度(CNFD)和神经分支密度(CNBD)等参数进行神经分割,可以很容易地分析角膜基底膜下神经丛的复杂结构。大量的二维角膜神经图像适合应用基于人工智能(AI)的深度学习算法(DLA)。事实上,DLA在角膜神经形态学量化方面的表现与手动量化相当,但优于自动量化。最近,我们使用3类AI模型进行的端到端分类在区分健康志愿者与患有和未患有周围神经病变的人方面显示出高灵敏度和特异性。我们认为,应用AI来帮助区分周围神经病变以及中枢神经退行性疾病具有很大的空间和需求。AI在增强CCM在周围和中枢神经退行性疾病管理中的诊断和预后效用方面具有巨大潜力。